Abbott has officially sealed its roughly $21 billion acquisition of Exact Sciences, closing the deal Monday and paying $105 per share to turn the Madison‑based cancer diagnostics heavyweight into a wholly owned Abbott subsidiary. The buyout immediately bulks up Abbott’s diagnostics footprint, pulling Exact’s Cologuard, Oncotype DX and other screening and precision oncology tests into its commercial machine. Exact is expected to stay rooted in Madison and run within Abbott’s diagnostics division as integration ramps up. Based on earlier company disclosures, the combined diagnostics business is projected to top $12 billion in annual sales once everything is folded together.
Crain’s Chicago Business was first to flag that the transaction had officially closed, giving the earliest public confirmation that control had changed hands. According to Crain’s Chicago Business, Abbott completed the all-cash purchase and Exact shareholders will receive $105 per share, following satisfaction of the remaining conditions required under the merger agreement.
Terms, Numbers And What Abbott Bought
Under the merger agreement announced last November, Abbott agreed to pay $105 in cash for each Exact share, a price that values the equity at roughly $21 billion and puts the enterprise valuation near $23 billion. Abbott also agreed to assume about $1.8 billion of Exact’s net debt, according to Exact Sciences investor materials. Those filings also project more than $3 billion in revenue for Exact this year and note that Abbott expects combined diagnostics sales to exceed $12 billion once the integration is complete. The same materials say Exact will keep its Madison operations and that senior leaders will help steer the transition.
Deal Financing
To help fund the cash-heavy takeover, Abbott tapped the bond markets in a big way, selling about $20 billion of notes in one of the largest U.S. investment grade offerings this year, according to Bloomberg Law. That multitranche sale, combined with cash Abbott already had on hand, was expected to cover the purchase price and related fees. Locking in that debt package was a key step in moving the deal from signed agreement to Monday’s closing.
What It Means For Madison
Exact Sciences has told investors it will maintain its Madison footprint, and that longtime CEO Kevin Conroy will shift into an advisory role to help guide the handoff, language that appears in the companies’ merger disclosures. For Madison’s life sciences scene, that means a major employer and research hub stays in town, even if the name on the corporate parent now reads Abbott. Previous coverage last November highlighted early takeover talk and underscored that Madison functions as Exact’s operational center, a point that looms large locally as the integration plays out.
Market Reaction And The Road Ahead
Industry observers say Abbott is pairing Exact’s cancer screening platform with a global commercial engine, a combination that could reshape how quickly certain tests reach patients. At the same time, they caution that the real test comes next, with reimbursement for newer multi cancer tests and the smoothness of the integration likely to determine whether the deal pays off. As reported by MedTech Dive, Abbott executives have framed the acquisition as a long term growth move in cancer diagnostics. Investors and clinicians will now be watching how quickly Abbott weaves Exact’s portfolio into its channels and whether insurers expand coverage for next generation screening tools…